Stay updated with breaking news from Multiple Myeloma Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Without a plethora of randomized and historic data to compare treatments, selection and sequencing strategies for patients with relapsed/refractory multiple myeloma must balance a multitude of factors, including adverse effect profiles, disease resistance mechanisms, and more.
With treatment advances over the last few years, and particularly in recent months, multiple myeloma has become treatable and may soon be curable.
With treatment advances over the last few years, and particularly in recent months, multiple myeloma has become treatable and may soon be curable.
Pfizer Inc. (NYSE:PFE) today announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval to ELREXFIO™ (elranatamab-bcmm) for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have recei
Ajai Chari, MD, discusses how the FDA approval of talquetamab addresses several unmet needs in relapsed/refractory multiple myeloma and expands on the agent’s efficacy data and safety profile observed in MonumenTAL-1.